Latigo Biotherapeutics, Inc.
Latigo Biotherapeutics develops non-opioid medicines intended to block pain transmission without addiction risk. Its drug candidates include LTG-001, an oral NaV1.8 inhibitor for acute pain; LTG-321, a NaV1.8 inhibitor targeting chronic musculoskeletal pain, initially osteoarthritis; and LTG-418, a NaV1.8 inhibitor for acute and chronic pain. The company is based in Thousand Oaks, California.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $LTGO in the last 30 days.
See all $LTGO insider activity →Latigo Biotherapeutics reported a narrower net loss of $20.95M in Q3 2026, with EPS at ($0.55), compared to ($24.8M) and ($29.5) in the prior year. R&D costs fell due to reduced onzotrigine trial expenses, while G&A expenses rose. The company has $401.2M in cash and expects funds to last into 2029. Onzotrigine trials met endpoints, with Phase 3 results expected in 2H 2027.
Latigo Biotherapeutics, Inc. (LTGO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Latigo Biotherapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights Phase 3 bunionectomy and open-label safety trials of onzotrigine remain on track for initiation with topline results expected in the second half of 2027 Company plans t
Latigo Biotherapeutics (LTGO) appointed Todd N. Smith as CEO, effective immediately. Nima Farzan, the outgoing CEO, will serve as a strategic advisor through 2027. Smith brings 30 years of experience in commercializing pain therapies. The company is focused on developing non-opioid pain treatments, with lead candidate onzotrigine in Phase 3 trials.
Over the past 7 days, AlphAI's AI scored 7 news stories mentioning LTGO (Latigo Biotherapeutics, Inc.). Coverage has skewed bullish: 1 bullish, 6 neutral, and 0 bearish.
Recent LTGO coverage spans ipo, earnings and financial news.
Quarterly loss narrowing may support the stock modestly.
The earnings release shows a net loss of $20.9 M and a strong cash runway, but no new guidance, suggesting limited immediate price move.
Leadership transition may improve execution of late‑stage programs and commercial rollout, but short‑term market reaction is uncertain.
Positive trial data may boost investor confidence and drive the stock higher.
Analyst upgrade with high price target may attract speculative buying.
AlphAI scores every news story that mentions LTGO with an AI model for sentiment and relevance, and aggregates insider trades from Latigo Biotherapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Latigo Biotherapeutics reported a narrower net loss of $20.95M in Q3 2026, with EPS at ($0.55), compared to ($24.8M) and ($29.5) in the prior year. R&D costs fell due to reduced onzotrigine trial expenses, while G&A expenses rose. The company has $401.2M in cash and expects funds to last into 2029. Onzotrigine trials met endpoints, with Phase 3 results expected in 2H 2027.
Latigo Biotherapeutics, Inc. (LTGO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Latigo Biotherapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights Phase 3 bunionectomy and open-label safety trials of onzotrigine remain on track for initiation with topline results expected in the second half of 2027 Company plans t
Latigo Biotherapeutics (LTGO) appointed Todd N. Smith as CEO, effective immediately. Nima Farzan, the outgoing CEO, will serve as a strategic advisor through 2027. Smith brings 30 years of experience in commercializing pain therapies. The company is focused on developing non-opioid pain treatments, with lead candidate onzotrigine in Phase 3 trials.
Latigo Biotherapeutics (LTGO), a clinical-stage biopharmaceutical company, is developing non-opioid pain treatments. Its lead candidate, Onzotrigine, showed positive results in post-operative pain, while LTG-321 is being evaluated for knee osteoarthritis. The company raised $397.4 million in its August 2026 IPO, funding operations into 2029.
Goldman Sachs recommends two under-the-radar IPO stocks: Latigo Biotherapeutics (LTGO) and Braveheart Bio (BRVE). LTGO, which develops non-opioid pain relief drugs, raised $345.6M in its IPO and has a market cap of $1.5B. Goldman's analyst sets a $73 price target, implying a 217% gain. BRVE focuses on hypertrophic cardiomyopathy treatments and plans Phase 3 trials next year. Both stocks have unanimous 'Buy' ratings from analysts.
Latigo Biotherapeutics (LTGO) reported Q2 2026 results, raising $397.4M in an upsized IPO. Cash reserves reached $55.0M pre-IPO. R&D expenses were $21.2M, G&A $4.6M, with a net loss of $25.8M. The company reported positive clinical trial results for onzotrigine and plans Phase 3 trials. It also initiated a Phase 2 trial for LTG-321.
Latigo Biotherapeutics (LTGO) reported a narrower Q2 loss of $(27.59) per share, a 24% improvement YoY, with no sales. The company plans to raise $256M-$288M via an IPO, offering 16M shares at $16-$18 each, listing on Nasdaq.
Latigo Biotherapeutics reported a net loss of $25.8M for 2Q 2026, matching the prior-year quarter, with a diluted net loss per share of $27.59. The company remains pre-revenue. Clinical trials for onzotrigine met key endpoints, and new trials are planned. The company expects cash runway into 2029.
Latigo Biotherapeutics reported positive pivotal trial results for onzotrigine in treating acute pain, with Phase 3 trials and data expected in 2027. The company raised $363.9M in an IPO, funding operations into 2029, but anticipates needing more capital for full development and commercialization. Risks include ongoing losses and regulatory challenges.
LTGO raised $397.4M in an IPO, extending its cash runway to 2029. The company reported positive Phase 2 trial results for onzotrigine in acute pain, with Phase 3 trials planned. Q2 2026 net loss was $25.8M, with R&D expenses slightly down year-over-year, according to its SEC filing.
